Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial
Multiple solid tumors
Phase 1 IDE574 dual KAT6/KAT7 lysine acetyltransferase inhibitor ± fulvestrant (ER degrader)
This first-in-human, open-label, multicenter Phase 1 study evaluates IDE574 (oral small-molecule dual inhibitor of the epigenetic writer enzymes KAT6 and KAT7) from IDEAYA Biosciences, as monotherapy dose escalation…
NCT07540572 First-in-human - New trial
Multiple solid tumors
Phase 1 DISP-10 DV-10 oncolytic adenovirus + BCMA-targeted CAR T in GI cancers
This Phase 1, multicenter, open-label study from Dispatch Biotherapeutics tests DISP-10, a combination of DV-10 (an adenovirus-based tumor-targeted viral therapy intended to inflame tumors and/or introduce antigenic…
NCT07544589 First-in-human - New trial
Multiple solid tumors
Phase 1/2a CKD-703 trial tests c-Met–targeting MMAE microtubule-inhibitor ADC in solid tumors/NSCLC.
This first-in-human, multicenter, open-label Phase 1/2a study evaluates CKD-703, an antibody-drug conjugate from Chong Kun Dang Pharmaceutical (CKD Pharm) that uses a c-Met–binding monoclonal antibody to deliver…
NCT07439094 First-in-human - New trial
Multiple solid tumors
Phase 1a/1b GTB-5550 B7-H3–targeted TriKE NK-cell engager (CD16 + IL-15)
This first-in-human Phase 1a/1b, open-label, non-randomized basket study evaluates GTB-5550, a camelid nanobody tri-specific killer engager (TriKE) designed to activate and expand endogenous NK cells while directing…
NCT07541573 First-in-human - Trial result Spotlight
Melanoma
DC-ATA personal dendritic cell vaccine + PD-1/LAG-3 blockade produced responses in all 6 response-evaluable patients with metastatic melanoma.
Personal DC-ATA is an autologous dendritic-cell vaccine loaded ex vivo with lysate from a short-term autologous tumor cell line (autologous tumor antigens), given here concurrently with standard immune checkpoint…
NCT03743298 - Trial result Spotlight
Melanoma
mRNA-4359 (PD-L1/IDO1 mRNA immunotherapy) + pembrolizumab drives 83% ORR in 1L metastatic melanoma (Phase 1/2)
mRNA-4359 is an intramuscular mRNA cancer antigen therapy encoding PD-L1 and IDO1 epitopes, designed to induce antigen-specific T cells against tumor and immunosuppressive cells, and was combined with pembrolizumab…
NCT05533697 - Trial result
Melanoma
Sotigalimab (intratumoral CD40 agonist) + pembrolizumab drives 50% ORR and abscopal responses in CPI‑naïve metastatic melanoma
Sotigalimab is an intratumoral, agonistic anti‑CD40 antibody designed to activate antigen-presenting cells (APCs) and “in situ” prime T cells; here it was combined with pembrolizumab (anti‑PD‑1) in a Phase I/II study…
NCT02706353 - Trial result
Sarcoma and GIST
Atezolizumab (PD-L1) Delivers 37-Month DoR in ASPS, with Fusion Subtype Driving Benefit
Atezolizumab (Tecentriq), an anti–PD-L1 monoclonal antibody, was given to patients with unresectable/metastatic alveolar soft part sarcoma (ASPS) in the pivotal single-arm Phase II Study ML39345 (NCT03141684; n=53)…
NCT03141684 - Trial result
Acute myeloid leukemia and MDS
FLAG-GO (CD33 ADC) lifts 5-year OS to 80% in frontline CBF-AML, blunting baseline mutation prognostic impact
Fludarabine/cytarabine/G-CSF (FLAG) is an intensive cytarabine-based induction/consolidation platform, and gemtuzumab ozogamicin (GO) is a CD33-directed antibody–drug conjugate; both were evaluated in a frontline…
NCT00801489 - Trial result
Cervical and other gynecologic cancers
Tisotumab vedotin (tissue factor ADC) triplet with pembrolizumab + carbo pushes 65.8% ORR (1L r/mCC) but with heavy discontinuations
Tisotumab vedotin (TV) is a tissue factor–directed antibody–drug conjugate delivering MMAE; in innovaTV 205/ENGOT-cx8/GOG-3024 (Phase 1b/2; NCT03786081), TV was combined with carboplatin (arm D, 1L; n=33) or…
NCT03786081 - Trial result Spotlight
Multiple myeloma
Cilta-cel (BCMA CAR-T) drives 71% 30‑mo PFS in standard‑risk lenalidomide‑refractory RRMM (CARTITUDE‑4)
Ciltacabtagene autoleucel (cilta-cel) is an autologous anti‑BCMA CAR‑T therapy evaluated in the randomized Phase 3 CARTITUDE‑4 trial (NCT04181827) in lenalidomide‑refractory relapsed/refractory multiple myeloma after…
NCT04181827 - Trial result Spotlight
Multiple myeloma
Cevostamab (FcRH5×CD3 bispecific) + pom-dex drives ~86–88% ORR and high MRD-negativity in BCMA-naïve RRMM
Cevostamab is an FcRH5×CD3 T-cell–engaging bispecific antibody; here it was combined with pomalidomide (IMiD) plus dexamethasone to augment T-cell activity in the Phase Ib CAMMA 1 Arm B randomized dose-expansion…
NCT04910568 - Trial result
Multiple myeloma
D-VRd (daratumumab anti-CD38) drives 65% sustained MRD− and >95% 4-year PFS in TE NDMM
Subcutaneous daratumumab (anti-CD38 mAb) plus bortezomib/lenalidomide/dexamethasone (D-VRd) with daratumumab+lenalidomide (D-R) maintenance was evaluated vs VRd with lenalidomide maintenance in the Phase 3 PERSEUS…
NCT03710603 - Trial result Spotlight
Liver and bile duct cancer
Muzastotug (ADG126) masked anti-CTLA-4 + atezolizumab/bevacizumab lifts ORR to 50% in 1L uHCC (tiny n)
Muzastotug (ADG126) is a protease-activated, Treg-depleting anti-CTLA-4 IgG1 designed for tumor-local activation (reported ~10× higher ADCC than ipilimumab) and was added to atezolizumab (PD-L1) + bevacizumab (VEGF)…
NCT04524871 - Trial result
Liver and bile duct cancer
Perioperative nivolumab ± relatlimab (PD-1/LAG-3) is surgery-safe and drives ~20%–27% major path responses in high-risk resectable HCC
Nivolumab is an anti–PD-1 monoclonal antibody, and relatlimab is an anti–LAG-3 monoclonal antibody (dual checkpoint blockade); both were tested as perioperative immunotherapy in an open-label, randomized,…
NCT04658147 - Trial result
Other cancers
Durvalumab (PD-L1) + platinum/pemetrexed: biomarker signals (BAP1/DDR, LOH) emerge despite DREAM3R OS miss in 1L pleural mesothelioma
Durvalumab is an anti–PD-L1 monoclonal antibody combined here with first-line platinum/pemetrexed chemotherapy in unresectable pleural mesothelioma (DREAM3R, randomized Phase 3; NCT04334759) that stopped early for…
NCT04334759 - Trial result
Sarcoma and GIST
Metronomic gemcitabine/doxorubicin/docetaxel + PD-1 nivolumab posts 57% ORR and 9.4-mo PFS in advanced angiosarcoma
Metronomic GDD plus nivolumab is a dose-dense chemo–immunotherapy regimen combining cytotoxics (gemcitabine, doxorubicin, docetaxel) with PD-1 blockade (nivolumab), evaluated in a Phase II study in advanced…
NCT04535713 - Trial result Spotlight
Non-small cell lung cancer
Zongertinib (HER2-selective irreversible TKI) hits 76% ORR and 14.4-mo PFS as 1L HER2-mutant NSCLC option
Zongertinib is an oral, irreversible HER2 (ERBB2) tyrosine kinase inhibitor designed to spare wild-type EGFR, evaluated in the Phase 1a/1b Beamion LUNG-1 multicohort trial (NCT04886804) at 120mg QD in previously…
NCT04886804 - Trial result Spotlight
Non-small cell lung cancer
Risvutatug rezetecan (B7-H3 TOP1i ADC) + adebrelimab (PD-L1) posts 47% cORR and 11.2-mo mPFS in 2L+ nsq-NSCLC
Risvutatug rezetecan (Ris-Rez; HS-20093/GSK5764227) is a B7-H3–targeted antibody-drug conjugate delivering a topoisomerase-1 inhibitor payload, combined here with adebrelimab, an anti–PD-L1 monoclonal antibody, in…
NCT06332170 - Trial result
Non-small cell lung cancer
Taletrectinib (CNS-penetrant ROS1 TKI) delivers 55.8% ORR and 9.7-mo mPFS after prior ROS1 TKI
Taletrectinib (Ibtrozi) is an oral, next-generation, CNS-active, selective ROS1 tyrosine kinase inhibitor evaluated in pooled Phase 2 TRUST-I (NCT04395677; prior crizotinib) and TRUST-II (NCT04919811; prior…
NCT04395677 - Trial result
Non-small cell lung cancer
Daraxonrasib (RMC-6236) RAS(ON) tri-complex inhibitor moves to Phase 3 vs docetaxel in RAS-mutant NSCLC
Daraxonrasib is an oral, RAS(ON) multi-selective tri-complex inhibitor designed to bind GTP-bound mutant and wild-type RAS, and is being advanced into RASolve 301, a global, open-label, randomized Phase 3 trial…
NCT06881784 - Trial result
Non-small cell lung cancer
IPH5201 (anti-CD39) + durvalumab (PD-L1) + platinum chemo posts 27.5% pCR in resectable NSCLC—signal enriches to 50% in PD-L1≥50%
IPH5201 is a blocking anti-CD39 monoclonal antibody (reduces adenosine generation by inhibiting CD39-mediated ATP breakdown) combined with durvalumab (anti–PD-L1) on top of neoadjuvant platinum-based chemotherapy in…
NCT05742607 - Trial result
Non-small cell lung cancer
ANS03 (type II ROS1/TRK TKI) shows 54.5% ORR in heavily pretreated ROS1+ NSCLC, including L2086F activity
ANS03 is a next-generation oral type II tyrosine kinase inhibitor targeting ROS1 and TRK designed to cover key acquired resistance mutations (including solvent-front mutations and the ROS1 Cβ6 L2086F). In the ongoing…
NCT06716138 - Trial result
Neuroendocrine and adrenal tumors
Peposertib (M3814) + DNA-PK Inhibition Sensitizes Lu-177 DOTATATE, Driving 21% ORR in Pre-treated SSTR+ GEP-NETs
Peposertib is an oral DNA-dependent protein kinase (DNA-PK) inhibitor designed to radiosensitize tumors by blocking nonhomologous end-joining DNA repair; here it was combined with Lu-177 DOTATATE peptide receptor…
NCT04750954 - Trial result
Neuroendocrine and adrenal tumors
[212Pb]VMT-α-NET (SSTR2-targeted alpha therapy) shows 39% ORR with clean early safety in PRRT-naïve NETs
[212Pb]VMT-α-NET is a SSTR2-targeted radiopharmaceutical that delivers the alpha-emitter lead-212 to SSTR2+ neuroendocrine tumors. In the Phase 1/2a dose-finding trial (NCT05636618) in well-differentiated…
NCT05636618 - Trial result Spotlight
Ovarian cancer
ZW191 (FRα-targeted ADC) posts 52% unconfirmed ORR in platinum-resistant ovarian/endometrial cancers (Phase 1)
ZW191 is a folate receptor α (FRα)-targeting antibody–drug conjugate (ADC) evaluated in the ongoing first-in-human ZWI-ZW191-101 Phase 1/2 study (NCT06555744); this Part 1 dose-escalation readout (data cut: Dec 1,…
NCT06555744 - Trial result Spotlight
Ovarian cancer
Relacorilant (glucocorticoid receptor antagonist) + nab-paclitaxel cuts death risk 35% in platinum‑resistant ovarian cancer
Relacorilant is an oral, selective glucocorticoid receptor (GR) antagonist intended to reverse GR-driven chemotherapy resistance; in the open-label Phase 3 ROSELLA trial (GOG-3073/ENGOT-ov72; NCT05257408),…
NCT05257408 - Trial result
Ovarian cancer
Pembrolizumab (PD-1) + weekly paclitaxel extends OS in platinum-resistant ovarian cancer (KEYNOTE-B96)
Pembrolizumab is an anti–PD-1 checkpoint inhibitor combined here with weekly paclitaxel (microtubule inhibitor), with optional bevacizumab (anti-VEGF) per investigator, in the randomized double-blind Phase 3…
NCT05116189 - Trial result
Brain and CNS tumors
Bortezomib (proteasome inhibitor; NF-κB/MGMT suppression) + temozolomide shows 24% RANO responses in recurrent MGMT-unmethylated GBM—biomarker signal tied to HSPBP1 insertion + intact apoptosis/NF-κB
LB014 reports a biomarker-driven readout from the ongoing Phase Ib/II NCT03643549 trial testing sequential bortezomib (a 26S proteasome inhibitor that can blunt NF-κB survival signaling and reduce MGMT) followed by…
NCT03643549 - Trial result
Acute lymphoblastic leukemia
PAX5-rearranged (PAX5r) B-ALL shows MRD-driven risk: 5-year EFS drops to 44% in high-risk kids
Across consecutive AIEOP-BFM pediatric ALL trials/registries (ALL 2000/2009/2017; 2001-2024), this retrospective series captured 165 children (<18y) with PAX5r BCP-ALL spanning 65 fusion partners (most commonly…
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.